Centauri Therapeutics Raises £6M In Series A Extension Funding Round

The company will use the capital to complete Phase I clinical studies for CTX-187, its lead candidate in the ABX-01 program, and to expand research activities in preparation for Phase II trials.

Led by CEO Dr. Henry Skinner, Centauri develops immunotherapies for infectious diseases and cancer using its proprietary Alphamer® technology. The platform employs synthetic molecules to redirect pre-existing natural antibodies to target pathogens or cancer cells.

AMR Action Fund, the world’s largest venture capital fund dedicated to antimicrobial therapeutics and diagnostics, will support Centauri in advancing CTX-187 through Phase I trials to generate key safety data for ongoing development.

Read Also - Heidelberg’s FLEXOO Raises €11M Series A Funding For Physical AI Sensor Technology

The funding will also enable preparation for Phase II studies. Dr. Henni-Karoliina Ropponen, Venture Associate at AMR Action Fund, has joined Centauri’s Board of Directors.

CTX-187, selected as Centauri’s first clinical candidate for 2025, is a broad-spectrum antimicrobial designed to treat multidrug-resistant Gram-negative bacteria. The compound combines dual mechanisms of action: immunotherapeutic effects via complement activation and opsonophagocytosis, alongside intrinsic antibacterial activity, expanding treatment options for vulnerable patients.

Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics, said: “We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections. This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset. I would like to thank the AMR Action Fund, as well as all of our existing investors and collaborators, for their support.”

Dr. Henry Skinner, Chief Executive Officer, AMR Action Fund, commented: “The growing burden of drug-resistant Gram-negative infections is one of the most pressing challenges in global health, leaving patients with limited and increasingly ineffective treatment options. Centauri’s approach represents a promising opportunity to address this challenge and we are pleased to support the team as they advance toward first-in-human studies.”

About Centauri Therapeutics

Centauri Therapeutics is a UK-based immunotherapy company developing innovative treatments for infectious diseases. Using its proprietary Alphamer® platform, it redirects natural antibodies to target pathogens, including multidrug-resistant bacteria, advancing novel therapeutic options.